The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective).
研究概览
简要总结
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
详细描述
Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.
排除标准
- •No beta blocker use,
- •no pregnancy,
- •no systemic steroids,
- •no severe asthma/copd,
- •no severe collagen vascular disorders,
- •no neoplastic or uncontrolled seizure activity,
- •no previous anaphylaxis, no significant cardiovsacular disease.
结局指标
主要结局
change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective).
时间窗: Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy.
Enrolled patients completed surveys pertinent to symptom scores, contrasting current status on immunotherapy compared (by recall) to a 12 month time point prior to initiation of therapy.
次要结局
- Changes in medication plus symptom aggregate score.(Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy.)
研究者
Frederick M. Schaffer, MD
Chief Medical Officer
United Allergy Services